American Journal of Clinical Nutrition, Vol 54, 311-315, Copyright © 1991 by The American Society for Clinical Nutrition, Inc

ORIGINAL RESEARCH COMMUNICATIONS

Resting energy expenditure and substrate oxidation in human immunodeficiency virus (HIV)-infected asymptomatic men: HIV affects host metabolism in the early asymptomatic stage

MJ Hommes, JA Romijn, E Endert and HP Sauerwein
Department of Endocrinology, University of Amsterdam, The Netherlands.

To study the effect of persistent human immunodeficiency virus (HIV) infection on host metabolism, we performed indirect calorimetry in 11 asymptomatic HIV-infected patients (Centers for Disease Control group II or III) who were seropositive for greater than or equal to 1 y, but who still had normal numbers of circulating CD4+ T cells, and in 11 healthy control subjects of similar age and relative body composition. HIV-infected patients had 8% (P less than 0.05) higher rates of resting energy expenditure than did control subjects. Fat-oxidation rates were significantly higher in the patients (means +/- SE: 2.90 +/- 0.08 vs 2.19 +/- 0.17 g.kg FFM-1.d-1, patients vs control subjects, P less than 0.01) whereas no significant differences in carbohydrate-oxidation rates between patients and control subjects were found. These alterations in metabolism were not associated with increased concentrations of catecholamines, cortisol, or thyroid hormones. Mean concentrations of interleukin 6 in the patients were increased only twofold when compared with healthy control subjects. The results indicate that HIV infection affects host metabolism in the early asymptomatic stage, before CD4+ T cell numbers start to decline.

This article has been cited by other articles:

				C. A Northrop-Clewes Interpreting indicators of iron status during an acute phase response - lessons from malaria and human immunodeficiency virus Ann Clin Biochem, January 1, 2008; 45(1): 18 - 32. [Abstract] [Full Text] [PDF]

				J. Sutinen and H. Yki-Jarvinen Increased resting energy expenditure, fat oxidation, and food intake in patients with highly active antiretroviral therapy-associated lipodystrophy Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E687 - E692. [Abstract] [Full Text] [PDF]

				G. R. Spollett Hyperglycemia in HIV/AIDS Diabetes Spectr, July 1, 2006; 19(3): 163 - 166. [Abstract] [Full Text] [PDF]

				M. J Batterham Investigating heterogeneity in studies of resting energy expenditure in persons with HIV/AIDS: a meta-analysis Am. J. Clinical Nutrition, March 1, 2005; 81(3): 702 - 713. [Abstract] [Full Text] [PDF]

				P. Crenn, B. Rakotoanbinina, J.-J. Raynaud, F. Thuillier, B. Messing, and J.-C. Melchior Hyperphagia Contributes to the Normal Body Composition and Protein-Energy Balance in HIV-Infected Asymptomatic Men J. Nutr., September 1, 2004; 134(9): 2301 - 2306. [Abstract] [Full Text] [PDF]

				L. Luzi, G. Perseghin, G. Tambussi, E. Meneghini, P. Scifo, E. Pagliato, A. Del Maschio, G. Testolin, and A. Lazzarin Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy Am J Physiol Endocrinol Metab, February 1, 2003; 284(2): E274 - E280. [Abstract] [Full Text] [PDF]

				M. van der Valk, P. Reiss, F. C. van Leth, M. T. Ackermans, E. Endert, J. A. Romijn, R. Heijligenberg, and H. Sauerwein Highly Active Antiretroviral Therapy-Induced Lipodystrophy Has Minor Effects on Human Immunodeficiency Virus-Induced Changes in Lipolysis, but Normalizes Resting Energy Expenditure J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 5066 - 5071. [Abstract] [Full Text] [PDF]

				S. M. Arpadi, P. A. Cuff, D. P. Kotler, J. Wang, M. Bamji, M. Lange, R. N. Pierson, and D. E. Matthews Growth Velocity, Fat-Free Mass and Energy Intake Are Inversely Related to Viral Load in HIV-Infected Children J. Nutr., October 1, 2000; 130(10): 2498 - 2502. [Abstract] [Full Text]

				P. P. G. Luna, P. S. Aguayo, M J. J. Exposito, A. P. Florit, P. G. Lorda, and J. S. Salvado Hypermetabolism and progression of HIV infection Am. J. Clinical Nutrition, August 1, 1999; 70(2): 299 - 300. [Full Text] [PDF]

				F. Jahoor, B. Gazzard, G. Phillips, D. Sharpstone, M. Delrosario, M. E. Frazer, W. Heird, R. Smith, and A. Jackson The acute-phase protein response to human immunodeficiency virus infection in human subjects Am J Physiol Endocrinol Metab, June 1, 1999; 276(6): E1092 - E1098. [Abstract] [Full Text] [PDF]

				F. R. Sattler, S. V. Jaque, E. T. Schroeder, C. Olson, M. P. Dube, C. Martinez, W. Briggs, R. Horton, and S. Azen Effects of Pharmacological Doses of Nandrolone Decanoate and Progressive Resistance Training in Immunodeficient Patients Infected with Human Immunodeficiency Virus J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1268 - 1276. [Abstract] [Full Text]

				J. de Metz, F. Sprangers, E. Endert, M. T. Ackermans, I. J. M. ten Berge, H. P. Sauerwein, and J. A. Romijn Interferon-gamma has immunomodulatory effects with minor endocrine and metabolic effects in humans J Appl Physiol, February 1, 1999; 86(2): 517 - 522. [Abstract] [Full Text] [PDF]

				Antiretroviral Therapy and Medical Management of Pediatric HIV Infection Pediatrics, October 1, 1998; 102(4): 1005 - 1062. [Full Text]

				S. M. Arpadi, M. N. B. Horlick, J. Wang, P. Cuff, M. Bamji, and D. P. Kotler Body Composition in Prepubertal Children With Human Immunodeficiency Virus Type 1 Infection Arch Pediatr Adolesc Med, July 1, 1998; 152(7): 688 - 693. [Abstract] [Full Text] [PDF]

				K. Mulligan, V. W. Tai, and M. Schambelan Effects of Chronic Growth Hormone Treatment on Energy Intake and Resting Energy Metabolism in Patients with Human Immunodeficiency Virus-Associated Wasting--A Clinical Research Center Study J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1542 - 1547. [Abstract] [Full Text]

				C. Grunfeld What Causes Wasting in AIDS? N. Engl. J. Med., July 13, 1995; 333(2): 123 - 124. [Full Text]